Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7844171 | 0.92 | ALDH1A1 (0.63) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL3824914 | 0.90 | ALDH1A1 (0.63) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL4337680 | 0.88 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL176357 | 0.88 | TTR (0.68) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL30825381 | 0.88 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| Hydrochloric Acid SCHEMBL9775617 | 0.87 | TTR (0.67) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL2747530 | 0.87 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL5518772 | 0.87 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL4217849 | 0.87 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL7566531 | 0.87 | ALDH1A1 (0.65) | ALDH1A1TDP1CYP3A4TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | claimed |
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | disclosed |
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2008-06-19 | — | — | US | disclosed |
| US-20050054691-A1 | Carboxylesterase inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054691-A1 | Carboxylesterase inhibitors | CES1, CES2, BCHE | ALDH1A1 227/4885TDP1 674/4885CYP3A4 15/4885 |
| US-20080146548-A1 | AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE | CES1, BCHE, CES2 | ALDH1A1 387/4885TDP1 928/4885CYP3A4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.